Phase 2 N=9 17AAG to Treat Kidney Tumors in Von Hippel-Lindau Disease
Hippel-Lindau Disease · Kidney Cancer
Primary: Number of Participants With a Renal Tumor Response — 0 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=3 A Phase I/II Trial for Intravitreous Treatment of Severe Ocular Von Hippel-Lindau Disease Using a Combination of the PDGF Antagonist E10030 and the VEGF Antagonist Ranibizumab
Von Hippel-Lindau Syndrome
Primary: Tabulation of Adverse Events — 13 adverse events
Phase 2 N=15 Contrast-enhanced Ultrasound as a Screening Tool for Kidney Cancer in Patients With Von-Hippel Lindau
Von-Hippel Lindau · Kidney Disease, Chronic
Primary: Comparison in Radiologist's Lesion Evaluation: CEUS Versus B-mode Ultrasound — 0.13; 0.20 Dichotomized score
Phase 2 N=32 Pazopanib Hydrochloride in Treating Patients With Von Hippel-Lindau Syndrome
Von Hippel-Lindau Syndrome
Primary: Overall Response Rate (Complete Response + Partial Response) — 13 Participants
N/A N=340 Natural History and Management of Pancreatic Lesions in Von Hippel-Lindau Disease
Von Hippel-Lindau Disease
Primary: Number of Patients With Pancreatic Lesions Defined by Simple Cysts, Microcystic Adenomas, Neuroendocrine Tumors & Other Solid Lesions of the Pancreas Who Had Significant…
Phase 2 N=4 MK-3795 (PT2385) for the Treatment of Von Hippel-Lindau Disease-Associated Clear Cell Renal Cell Carcinoma (MK-3795-003)
VHL Gene Mutation · VHL · VHL Syndrome
Primary: Overall Response Rate (ORR) in VHL Disease-Associated ccRCC Tumors — 0.0 Percentage of Participants
Phase 3 N=15 Recombinant Von Willebrand Factor in Subjects With Severe Von Willebrand Disease Undergoing Surgery
Von Willebrand Disease
Primary: Overall Hemostatic Efficacy as Assessed by the Investigator (Hemophilia Physician) — 11; 4; 7; 0 Participants
Phase 3 N=20 Prevent Postpartum Hemorrhage in Women With Von Willebrand Disease: The VWD-WOMAN Trial
Von Willebrand Diseases · Postpartum Hemorrhage
Primary: Volume of Quantitative Blood Loss at Delivery — 727.0; 539.7 mL
Phase 2 N=37 Phase II Study of Vandetanib in Individuals With Kidney Cancer
Renal Cancer · Von Hippel Lindau
Primary: Overall Response Rate. — 3; 0; 75; 0 percentage of participants
Phase 3 N=35 A Study of Recombinant Von Willebrand Factor (rVWF) in Pediatric and Adult Participants With Severe Von Willebrand Disease (VWD)
Von Willebrand Disease (VWD)
Primary: Spontaneous Annualized Bleeding Rate (sABR) — 1.430; 1.040; 0.000; 3.022 spontaneous bleeds per year
Phase 3 N=12 Efficacy, PK, Immunogenicity and Safety of Wilate in Severe Von Willebrand Disease (VWD) Patients <6 Years of Age
Von Willebrand Disease
Primary: Total Annualised Bleeding Rate (TABR) During Prophylactic Treatment With Wilate. — 4.6; 3.7 Annualized number of bleeding episodes
Phase 3 N=37 Pharmacokinetics, Safety and Efficacy of Recombinant Von Willebrand Factor (rVWF) in the Treatment of Bleeding Episodes in Von Willebrand Disease (VWD)
Von Willebrand Disease
Primary: Percentage of Participants With Treatment Success for Treated Bleeding Episodes — 100.0 Percent of participants
N/A N=265 Type 3 Von Willebrand International Registries Inhibitor Prospective Study
Type 3 Von Willebrand's Disease
Primary: Centralized Factor VIII (FVIII) Procoagulant Activity (FVIII:C) Laboratory Test for Type 3 Von Willebrand's Disease (VWD3) Diagnosis — 2.42 IU/dL
N/A N=48 Gingival Bleeding and Von Willebrand Disease Typ 2 and 3
Gingival Bleeding · Von Willebrand Diseases
Primary: Bleeding on Probing (BOP) — 14.5; 12.3 percentage of sites
Phase 3 N=23 rVWF IN PROPHYLAXIS
Von Willebrand Disease
Primary: Ratio of Annualized Bleeding Rate (ABR) for Spontaneous Bleeding Episodes (BEs) (On-study ABR / Historical ABR) Assessed by Investigator During Prophylactic Treatment…